Multicenter Evaluation Of Neurofilaments In Early Symptom Onset Amyotrophic Lateral Sclerosis
Emily Feneberg, MD, Patrick Oeckl, PhD, Petra Steinacker, PhD, Federico Verde, MD, Christian Barro, Philip Van Damme, MD, PhD, Elizabeth Gray, PhD, Julian Grosskreutz, MD, Claude Jardel, PharmD, PhD, Jens Kuhle, MD, PhD, Sonja Koerner, MD, Foudil Lamari, MD, PhD, Maria del Mar Amador, MD, Benjamin Mayer, PhD, Claudia Morelli, MD, Petra Muckova, PhD, Susanne Petri, MD, Koen Poesen, PharmD, PhD, Joost Raaphorst, MD, François Salachas, MD, Vincenzo Silani, MD, Beatrice Stubendorff, PhD, Martin R. Turner, PhD, Marcel M. Verbeek, PhD, MSc, Jochen H. Weishaupt, MD, Patrick Weydt, MD, Albert C. Ludolph, MD, and Markus Otto, MD
Objective To examine neurofilament (Nf) concentrations according to symptom onset and clinical diagnostic certainty categories of amyotrophic lateral sclerosis (ALS).
Methods We measured Nf light chain (NfL) and phosphorylated Nf heavy chain (pNfH) CSF and NfL serum levels in patients with ALS with first symptom onset ≤6 months (n = 54) or >6 months (n = 135) from sampling, and patients with other neurologic diseases, differential diagnoses of a motor neuron disease (MND mimics), and other MND variants to determine the diagnostic accuracy in patients with ALS with early symptom onset. Samples were received multicentric and analyzed by ELISA and Simoa platform and related to other clinical measures.
Results NfL and pNfH in CSF and NfL in serum were increased in early and later symptomatic phase ALS (p < 0.0001). CSF and serum NfL and CSF pNfH discriminated patients with ALS with early symptom onset from those with other neurologic diseases and MND mimics with high sensitivity (94%, 88%, 98%, and 89%, 100%, 78%) and specificity (86%, 92%, 91%, and 94%, 90%, 98%) and did not vary between clinical diagnostic categories of ALS in the early symptomatic phase group. Baseline NfL and pNfH levels were not significantly different in patients with ALS with clinical progression to definite or probable ALS at follow-up.
Conclusion The measurement of Nf has potential to enhance diagnostic accuracy of ALS in those presenting soon after symptom onset, and is measurable across multiple centers.
Classification of evidence This study provides Class II evidence that CSF and serum Nf concentrations discriminate ALS with early symptom onset from other neurologic diseases.
Share this page